Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
Anthos is a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), one of the worlds’ leading pharmaceutical companies. The company is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular disease.
Anthos’ priority R&D program is abelacimab, a potent monoclonal antibody directed at novel targets within the coagulation cascade: Factor XI and XIa. Early research data indicate that abelacimab has the potential to provide effective protection from thromboembolic events whilst reducing the hazard of a clinically significant bleeding risk – presenting an entirely new paradigm within the anticoagulation field.
More than 1 in 4 people worldwide die from thromboembolic events1,2 – a death toll due in part to the widespread underutilization, under-dosing and early discontinuation of anticoagulation.3,4 A strong deterrent to optimal prescribing is fear of major bleeds. The risk of bleeding – especially in frail, elderly patients not represented in clinical trials – stems from the fact that all conventional anticoagulants, including DOACs, impact physiological hemostasis as well as pathological thrombosis.
New scientific understanding shows that taking aim at an entirely new target, Factor XI, could enable pharmacological ‘uncoupling’ of the physiological hemostasis and pathological thrombosis pathways, potentially fulfilling the ultimate ambition of vital protection from thromboembolic events whilst reducing the hazard of a clinically significant bleeding risk.
Abelacimab is a potent biologic molecule designed to achieve profound Factor XI suppression through dual activity against Factor XI and its activated counterpart, Factor XIa. Created for the heterogeneous real world and for use in different healthcare settings, abelacimab has the potential to address a major unmet need.
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors. Investments are of sufficient scale to allow companies or products to reach meaningful value inflection points and are made in conjunction with hands-on operational leadership. In launching this new platform, Blackstone acquired Clarus, a leading global life-sciences firm.
Anthos Therapeutics is Developing a Hemostasis-Sparing Anticoagulant to Reduce the Hazard of BleedingRead More
Anthos Therapeutics dubbed one of the fiercest biotech companies in the worldRead More
Blackstone Life Sciences and Novartis Create Anthos Therapeutics to Develop Innovative Targeted Medicines for Cardiovascular DiseaseRead More
Koch AW, Schiering N, Melkko S, et al. MAA868—a novel FXI antibody with a unique binding mode—shows durable effects on markers of anticoagulation in humans. Blood 2019; blood-2018-10-880849.https://doi.org/10.1182/blood-2018-10-880849
Accessed February 21, 2019